127 related articles for article (PubMed ID: 38679642)
1. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of incidental prostate cancer in the United States.
Scheipner L; Incesu RB; Morra S; Baudo A; Assad A; Jannello LMI; Siech C; de Angelis M; Barletta F; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Tilki D; Longo N; Carmignani L; De Cobelli O; Ahyai S; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2023 Oct; ():. PubMed ID: 37872250
[TBL] [Abstract][Full Text] [Related]
3. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
4. Other-cause mortality in incidental prostate cancer.
Di Bello F; Baudo A; de Angelis M; Jannello LMI; Siech C; Tian Z; Goyal JA; Collà Ruvolo C; Califano G; La Rocca R; Morra S; Acquati P; Saad F; Shariat SF; Carmignani L; de Cobelli O; Briganti A; Chun FKH; Longo N; Karakiewicz PI
Prostate; 2024 Jun; 84(8):731-737. PubMed ID: 38506561
[TBL] [Abstract][Full Text] [Related]
5. Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis.
Liu S; Wang XY; Huang TB; Niu Q; Yao K; Song X; Zhou SY; Chen Z; Zhou GC
Ann Palliat Med; 2020 Jul; 9(4):1708-1717. PubMed ID: 32527134
[TBL] [Abstract][Full Text] [Related]
6. Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate.
Nunez R; Hurd KJ; Noble BN; Castle EP; Andrews PE; Humphreys MR
Int J Urol; 2011 Jul; 18(7):543-7. PubMed ID: 21592233
[TBL] [Abstract][Full Text] [Related]
7. Differences in survival of prostate cancer Gleason 8-10 disease and the establishment of a new Gleason survival grading system.
Zhou Y; Lin C; Hu Z; Yang C; Zhang R; Ding Y; Wang Z; Tao S; Qin Y
Cancer Med; 2021 Jan; 10(1):87-97. PubMed ID: 33135335
[TBL] [Abstract][Full Text] [Related]
8. How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
Jin K; Qiu S; Li J; Zheng X; Tu X; Liao X; Yang Y; Yang L; Wei Q
Cancer Med; 2019 Jul; 8(7):3370-3378. PubMed ID: 31066510
[TBL] [Abstract][Full Text] [Related]
9. Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study.
Herden J; Schwarte A; Boedefeld EA; Weissbach L
Urol Int; 2021; 105(5-6):428-435. PubMed ID: 33517336
[TBL] [Abstract][Full Text] [Related]
10. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
11. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis.
Bandini M; Pompe RS; Marchioni M; Tian Z; Gandaglia G; Fossati N; Tilki D; Graefen M; Montorsi F; Shariat SF; Briganti A; Saad F; Karakiewicz PI
World J Urol; 2018 Jan; 36(1):7-13. PubMed ID: 29063268
[TBL] [Abstract][Full Text] [Related]
12. Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis.
Yanagisawa T; Mori K; Kawada T; Motlagh RS; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Aydh A; König F; Pallauf M; Pradere B; Miki J; Kimura T; Egawa S; Shariat SF
Urol Oncol; 2022 Jul; 40(7):315-330. PubMed ID: 35562311
[TBL] [Abstract][Full Text] [Related]
13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
14. Robot-assisted partial nephrectomy for large renal masses: a multi-institutional series.
Delto JC; Paulucci D; Helbig MW; Badani KK; Eun D; Porter J; Abaza R; Hemal AK; Bhandari A
BJU Int; 2018 Jun; 121(6):908-915. PubMed ID: 29357404
[TBL] [Abstract][Full Text] [Related]
15. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Fossati N; Gandaglia G; Gallina A; Abdollah F; Shariat SF; Montorsi F; Saad F; Tilki D; Briganti A; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):381-388. PubMed ID: 29366856
[TBL] [Abstract][Full Text] [Related]
16. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
17. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.
Knipper S; Dzyuba-Negrean C; Palumbo C; Pecoraro A; Rosiello G; Tian Z; Briganti A; Saad F; Tilki D; Graefen M; Karakiewicz PI
Int Urol Nephrol; 2020 Jan; 52(1):59-66. PubMed ID: 31542882
[TBL] [Abstract][Full Text] [Related]
18. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
19. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
[TBL] [Abstract][Full Text] [Related]
20. Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer.
Miao Q; Wei Z; Liu C; Ye Y; Cheng G; Song Z; Chen K; Zhang Y; Chen J; Yue C; Ruan H; Zhang X
Front Oncol; 2023; 13():1130680. PubMed ID: 37207146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]